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Visceral leishmaniasis (VL), caused by the protozoan parasites
Leishmania donovani and Leishmania infantum, is one of the ma-
jor parasitic diseases worldwide. There is an urgent need for new
drugs to treat VL, because current therapies are unfit for purpose
in a resource-poor setting. Here, we describe the development of a
preclinical drug candidate, GSK3494245/DDD01305143/compound
8, with potential to treat this neglected tropical disease. The com-
pound series was discovered by repurposing hits from a screen
against the related parasite Trypanosoma cruzi. Subsequent opti-
mization of the chemical series resulted in the development of a
potent cidal compound with activity against a range of clinically
relevant L. donovani and L. infantum isolates. Compound 8 dem-
onstrates promising pharmacokinetic properties and impressive
in vivo efficacy in our mouse model of infection comparable with
those of the current oral antileishmanial miltefosine. Detailed
mode of action studies confirm that this compound acts principally
by inhibition of the chymotrypsin-like activity catalyzed by the β5
subunit of the L. donovani proteasome. High-resolution cryo-EM
structures of apo and compound 8-bound Leishmania tarentolae
20S proteasome reveal a previously undiscovered inhibitor site
that lies between the β4 and β5 proteasome subunits. This induced
pocket exploits β4 residues that are divergent between humans
and kinetoplastid parasites and is consistent with all of our exper-
imental and mutagenesis data. As a result of these comprehensive
studies and due to a favorable developability and safety profile,
compound 8 is being advanced toward human clinical trials.
Leishmania | proteasome | cryo-EM | drug discovery
Visceral leishmaniasis (VL), the most serious form of leish-maniasis, is invariably fatal if left untreated (1). This
neglected tropical disease is caused by infection with the pro-
tozoan parasite Leishmania donovani or Leishmania infantum.
There are over 600 million people at risk from infection, and the
annual death toll is 20,000–40,000 (2). The disease is spread
through the bite of infected sandflies, giving rise to a systemic
infection in the human host with diverse symptoms, including
fever, weight loss, anemia, and hepatosplenomegaly. More than
90% of VL cases are reported in India, Sudan, southern Sudan,
Ethiopia, Kenya, Somalia, and Brazil; however, this disease has a
worldwide presence, with cases in Asia, East Africa, South America,
and the Mediterranean region (3). HIV/VL coinfections are com-
monplace and can accelerate the progression of both diseases (4).
Significantly, VL-associated morbidity has a considerable economic
impact, contributing to a perpetual cycle of poverty in some of the
poorest regions of the world.
Current available treatments for VL are limited to pentavalent
antimonials, amphotericin B, paromomycin, and miltefosine,
the only oral treatment available. These treatments have seri-
ous drawbacks, including prolonged treatment duration (20–30
d for antimonials and 28 d for miltefosine and amphotericin B
deoxycholate), parenteral administration (amphotericin B, anti-
monials, and paromomycin), low tolerability (antimonials and
amphotericin B deoxycholate), teratogenicity (miltefosine),
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treatment failures (5, 6) (paromomycin, miltefosine, and antimo-
nials), and requirement for cold storage and high cost (liposomal
amphotericin B). These drugs also show significant geographical
variation in effectiveness for reasons that are poorly understood. In
particular, none of the current VL drugs have high levels of efficacy
in East Africa (7, 8). Thus, identification of a low-cost, safe, effec-
tive, oral, and short-course drug for VL is urgently needed (9).
Here, we report the discovery of a preclinical candidate for the
treatment of VL that acts principally by inhibition of the chymo-
trypsin-like activity catalyzed by the β5 subunit of the L. donovani
proteasome.
Results and Discussion
Discovery of Compound 8. Identification of new chemical entities
capable of treating kinetoplastid infections has proven to be
extremely challenging. There are few robustly validated drug
targets in the kinetoplastid parasites, making target-based ap-
proaches speculative (10), and drug discovery programs are
usually reliant on phenotypic screening to find suitable chemical
start points. The identification of compounds with activity
against these intracellular parasites has also proven difficult,
particularly in the case of L. donovani, where the mammalian
stage of the parasite, the amastigote, resides within human
macrophages. High-throughput screening against the intra-
macrophage stage of the parasite is plagued by extremely low hit
rates; however, activity for a compound series in this assay usu-
ally translates into activity in animal models of disease if phar-
macokinetic properties can be optimized (11, 12).
The hit compound 1 was identified from phenotypic screening
of a 15,659-compound diversity library against the related
kinetoplastid parasite Trypanosoma cruzi [EC50 = 0.22 μM; 95%
confidence interval (95% CI) = 0.087–0.36 μM; n = 3] (SI Ap-
pendix, Fig. S1 shows the screening progression cascade). An
initial scaffold hop led to 2, which maintains activity against T.
cruzi (Fig. 1) (EC50 = 0.93 μM; 95% CI = 0.47–1.4 μM; n = 4).
We hypothesized that, in view of their structural similarity, 1 and
2 probably shared the same mechanism of action. Screening both
compounds in our L. donovani intramacrophage assay, where the
amastigotes are cultured in differentiated THP-1 cells (13), gave
EC50 values for compound 1 of 5.7 μM (95% CI = 2.3–14 μM;
n = 5) and for compound 2 of 26 μM (95% CI = 13–52 μM; n =
4). Compounds 1 and 2 also demonstrated good selectivity over
mammalian cell growth inhibition (THP-1 cells; EC50 > 50 μM),
although both did show poor in vitro metabolic stability as shown
by their rapid degradation when incubated with mouse liver
microsomes (Fig. 1). Compound 2 showed improved kinetic
solubility, and therefore, we decided to focus on the imidazo-
pyrimidine scaffold for additional optimization.
The poor in vitro metabolic stability was improved by substituting
at the six position of the pyrimidine ring as exemplified by 3
[intramacrophage EC50 value of 4.2 μM; 95% CI = 1.5–12 μM; n =
4; intrinsic clearance when incubated with mouse liver microsomes
(CLint) = 1.8 mL/min per gram]. The furan group is potentially
metabolically liable, and if metabolized, it could give rise to reactive
intermediates. It proved possible to replace the furan amide with a
pyrrolidinyl urea (4), which maintained potency against the parasite
(EC50 = 3.3 μM; 95% CI = 1.4–7.6 μM; n = 4; CLint = 0.59 mL/min
per gram). Replacement of the 6-ethoxy substituent by a morpho-
line gave 5, with good metabolic stability (CLint = 0.76 mL/min per
gram) and improved solubility (charged aerosol detector = 43 μg/
mL), although with a slight decrease in its antileishmanial activity
(EC50 = 8.2 μM; 95% CI = 5.4–11 μM; n = 3). Addition of fluorine
to the four position of the phenyl ring to give 6a improved potency
by >10-fold (EC50 = 0.6 μM; 95% CI = 0.35–1.1 μM; n = 5). Po-
tency could be slightly enhanced by replacement of morpholine with
phenyl to give 6 (EC50 = 0.15 μM; 95% CI = 0.1–0.23 μM; n = 7).
Compound 6a was shown to be positive in an Ames assay, indi-
cating a genotoxic liability, and therefore, we attempted to develop
compounds that were negative in the Ames assay. Furthermore, 6
and 6a had poor solubility in the biorelevant fasted simulated in-
testinal fluid (FaSSIF) assay.
A key strategy to tackle genotoxicity and also improve sol-
ubility was to replace the core bicycle via scaffold hopping
(14). This involved varying the position and number of het-
eroatoms in the bicyclic system as well as switching the left-
hand six-membered and right-hand five-membered rings. This
led to two scaffolds that were selected for additional evalua-
tion: imidazo[1,2-b][1,2,4]triazines (exemplified by 7 and 7a)
and imidazo[1,2-a]pyrimidines (exemplified by compound 8). The
phenyl analog 7 gave an EC50 value of 0.35 μM (95% CI = 0.25–
0.5 μM; n = 9), and 7a returned an EC50 of 0.41 μM (95% CI =
0.35–0.47 μM; n = 49) in the intramacrophage assay. Unfortu-
nately, the aniline resulting from the removal of the urea moiety in
7a was positive in an Ames assay, and additional development was
stopped; however, the high potency of compound 7 led to it being
selected as a tool compound for mechanism of action studies. The
imidazo[1,2-a]pyrimidine (8) showed slightly lower potency with
EC50 of 1.6 μM (95% CI = 1.1–2.2 μM; n = 11), but this was
balanced by improved FaSSIF solubility (180 μg/mL). It showed
good in vitro metabolic stability (CLint = 0.8 mL/min per gram) and
selectivity over mammalian cells. Both 8 and the corresponding
free aniline gave negative results in the Ames assay. All of these
factors led to the selection of 8 for more detailed profiling.
Due to the global spread of the disease, future antileishmanial
drugs must demonstrate efficacy against a diverse range of
clinical strains from geographical locations (15). This was found
to be the case for 8, which maintained potency in vitro against
clinical strains (EC50 ∼ 1 μM), including two strains isolated in
East Africa (LV9 and SUKA001) and two strains from India
Fig. 1. The evolution of the series from hits to 8. Potencies against intra-
macrophage amastigotes and against THP-1 cells are shown. Data are from
at least three independent replicates. CAD solubility, charged aerosol de-
tector solubility.
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(DD8-WT and BHU1), with the latter being antimony resistant
(SI Appendix, Table S1). To gain insight into the concentration
and duration of treatment required to kill the parasites, 8 was
assessed in our well-established axenic amastigote rate-of-kill
assay (16). Compound 8 induced parasite cell death at a mini-
mum concentration of 620 nM after 72 h. As compound con-
centrations were increased, the time to kill was reduced to 48 h
(SI Appendix, Fig. S2).
In Vivo Efficacy and PK. Given its promising in vitro profile, 8 was
progressed to a mouse model of VL infection (17). Initial phar-
macokinetic studies in mice indicated that the compound had suf-
ficient oral bioavailability to obtain free compound levels in excess
of EC99 values when dosed twice daily at 25 mg/kg. Infected mice
were dosed at 3, 10, or 25 mg/kg orally twice a day for 10 consec-
utive days. Two days after the termination of treatment, mice were
euthanized, and the parasite burdens in their livers were de-
termined. When dosed orally at 25 mg/kg, compound 8 elicited
a >95% reduction of parasite load, similar efficacy to that seen with
miltefosine dosed orally at 30 mg/kg once daily in the same model
(Fig. 2 and SI Appendix, Table S2). In this dose-ranging experiment,
we demonstrated that the ED50, ED90, and ED99 values for com-
pound 8 after 10-d treatments orally twice a day were 8.9, 16, and 30
mg/kg, respectively. In comparison, the reported ED90 for miltefo-
sine in a similar mouse model was 27 mg/kg once daily (18).
The PK properties of 8 are such that it can be orally dosed to
reach efficacious levels in a range of preclinical species, including
mouse, rat, and dog (SI Appendix, Table S3). Relatively low oral
bioavailability (F) was observed in mouse (F = 18%), although
bioavailability was moderate in rat and dog (F = 35 and 46%, re-
spectively). The volume of distribution at steady state indicated that
the compound had distribution beyond the bloodstream (2.2, 1.0,
and 1.3 L/kg in mouse, rat, and dog, respectively). Compound 8 had
moderate blood clearance in mice and dogs (41 and 30 mL/min per
kilogram, respectively) and low clearance in rat (17 mL/min per
kilogram).
Safety Profile. Compound 8 has exhibited no noteworthy safety
liabilities at any dose tested during extensive in vitro profiling, in-
cluding genotoxicity (Ames and mouse lymphoma tests) (SI Appen-
dix, Tables S4 and S5). After a rat 7-d toxicology study (at doses up to
300 mg/kg), no significant safety or tolerability liabilities were de-
tected. Thus, 8 is expected to have a safety margin of at least 37-fold
by comparing the exposure in the rat at 300 mg/kg (980 μg/h per
mililiter) to the observed exposure giving >95% parasite burden re-
duction (27 μg/h per mililiter when 8 was dosed at 25 mg/kg twice a
day for 10 days).
Overall, 8 is a small molecule with good physicochemical
properties that is highly efficacious (in both in vitro and in vivo
assays), demonstrates a desirable safety profile, and shows bal-
anced PK properties. As a result of these promising findings, 8
was selected as a preclinical candidate and is now being pro-
gressed toward human clinical trials.
Mode of Action Studies. Elucidating the mode of action of novel
chemical series can be enormously beneficial in drug discovery
campaigns. Since there is no roadmap establishing the mode of
action of bioactive small molecules, several complementary
methodologies were used with representative analogs of this
compound series as chemical tools.
Whole-Genome RNAi Library Screening. Initially, our studies of the
mechanism of action of this compound series focused primarily
on compound 7. Compounds from this series, including 7, are
equally potent against both L. donovani and Trypanosoma brucei,
enabling us to utilize our genome-wide RNAi (RITseq) library in
T. brucei (19) and suggesting that this series of compounds could
exhibit a broad spectrum of antikinetoplastid activity. The library
was exposed to a typically lethal dose (three times the EC50
value) of 7. Under tetracycline induction, each trypanosome in
the library produces dsRNA from integrated RNAi target frag-
ments (Fig. 3A). The resulting target knockdown has the po-
tential to confer a selective advantage under drug pressure.
RITseq was used to generate a readout from the parasite pop-
ulation that tolerated 7. Screening of 7 against the RITseq library
identified 10 “hits” with functional domains commonly found in
proteins of the ubiquitin–proteasome recycling pathway (Fig. 3A
and SI Appendix, Table S7). The top two hits from these
screening studies (Tb927.9.15260 and Tb927.8.6620) were fur-
ther investigated, and individual stem-loop RNAi studies con-
firmed that knockdown of the RNA transcripts associated with
these genes conferred (approximately twofold) resistance to
compound 7 (SI Appendix, Figs. S3 and S4). We suggest that
knockdown of nonessential ubiquitin proteasome activity in-
creases capacity and flux through ubiquitin proteasome pathways
that are essential for viability. Collectively, these data implicated
the ubiquitin proteasome system in mechanism(s) of resistance
and potentially, mechanism(s) of action of compounds from
this series.
Resistance Generation. L. donovani cell lines resistant to 7 were
generated in vitro by exposing promastigotes to stepwise in-
creasing concentrations of compound. The resulting clones
demonstrated >100-fold resistance to 7 (Fig. 3B) and were also
cross-resistant to all of the compounds from this series that were
tested, including 8 (Fig. 3C), confirming that compounds from
this series are likely to share a similar mechanism of action. At
this point, Khare et al. (20) published their studies of GNF6702,
a structurally related compound that selectively inhibits the
kinetoplastid proteasome. They carried out mode of action
studies in T. cruzi and identified the proteasome as the target of
their inhibitor, suggesting that the compound acted at the in-
terface of the β4 and β5 subunits. Guided by these studies and by
the results of our own RITseq library screen, we carried out
targeted DNA sequencing of the genes encoding the subunits of
the L. donovani proteasome. Sequencing of three independently
generated resistant clones revealed homozygous mutations
within the genes encoding the β4 and β5 subunits. Specifically,
clones RES I and II maintained mutations encoding a G197C
substitution in the β5 subunit as well as a T30A substitution in
the β4 subunit. RES III maintained solely a G197S substitution
in the β5 subunit.
To determine the role of these mutations in resistance to 7 and
other compounds from this series, we engineered L. donovani
promastigote lines that overexpressed either β5G197C or β4T30A.
Fig. 2. In vivo efficacy and blood exposure of 8. (A) Therapeutic efficacy of 8
in a mouse model of VL (L. donovani, LV9). Data correspond to mean Leishman
Donovan units (LDUs) for mice treated with 8, miltefosine, or vehicle alone (n =
5). Unpaired t tests confirmed that the reduction in parasite burden evident in all
treated mice is statistically significant compared with untreated control animals,
with *P = 0.0441 and **P = 0.0037 formice treatedwith compound 8 at 3 and 10
mg/kg, respectively, and P < 0.0001 for mice treated with miltefosine and
compound 8 at 25 mg/kg. Blood levels of 8 after a single i.v. dose at 3 mg/kg (B)
or a single oral dose at 10 mg/kg (C) to male CD-1 mice (blue), male SD rats (red),
and male beagle dogs (green). The profiles are represented as mean ± SD. The y
axis is represented as a logarithmic scale. b.i.d., twice a day.
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Overexpression of the mutated β5 subunit reduced the suscep-
tibility of WT parasites to 7 by fourfold, confirming the role of
this mutation in resistance (Fig. 3D). However, overexpression of
β4T30A did not alter susceptibility to compounds from this series.
These data are entirely consistent with our compounds targeting
the proteasome of L. donovani, specifically the chymotrypsin-like
degradation activity catalyzed by the β5 subunit.
Inhibition of the Chymotrypsin-Like Activity of the L. donovani Proteasome.
An in vitro assay was developed that enabled the chymotrypsin-like
activity and additional proteolytic activities associated with the pro-
teasome to be directly monitored within proteasome-enriched parasite
cell lysates. Likewise, human proteasome from two sources (i.e.,
commercially pure 26S and enriched proteasome fractions from THP-
1 lysates) was tested using the same biochemical assays. Compound 8
specifically inhibited the chymotrypsin-like activity of the L. donovani
proteasome in a dose-dependent manner (mean IC50 = 0.16 ±
0.01 μM) (Fig. 4A) but had no effect on the caspase or trypsin ac-
tivities (SI Appendix, Fig. S5). The chymotrypsin-like activity of human
proteasome was moderately inhibited by 8 (mean IC50: purified 26S =
13 ± 0.88 μM; enriched THP-1 extracts IC50 = 40 ± 12.4 μM);
however, a significant selectivity window of >100-fold was maintained.
Of particular note is the significant correlation between anti-
leishmanial activity and the inhibition of proteasome chymotrypsin
activity for a diverse set of compounds belonging to the same
chemical series as 8 (Fig. 4B). This represents additional evidence of
the proteasome as the predominant target of this compound series
and that inhibition of proteasome activity accounts for the anti-
parasitic activity of 8 and its analogs. As expected for a proteasome
inhibitor, 8 induces the accumulation of ubiquitylated proteins in
the parasite cell in a dose-dependent manner (SI Appendix, Fig. S6).
The subunit specificity of 8 was assessed using the human
active site probe Me4BodipyFL-Ahx3Leu3VS, commercially
known as UbiQ-018 (Fig. 4C). This probe covalently labels all
three catalytic subunits in human proteasomes (21). In contrast,
only the β2 and β5 active sites of the parasite proteasome were
fluorescently labeled by UbiQ-018 (SI Appendix, Table S8). In
support of our enzymatic analyses, the presence of 8 selectively
blocked UbiQ-018 labeling of the β5 subunit in Leishmania ly-
sates while having no effect on binding to subunit β2. In another
demonstration of compound 8 selectivity, incubation with this
compound had no effect on UbiQ-018 labeling of the three
catalytic subunits of the human proteasome. Furthermore, la-
beling of β5 in proteasomes prepared from our Leishmania-re-
sistant cell lines could not be abolished by the presence of 8.
Classical proteasome inhibitors (e.g., bortezomib) blocked all
subunits of the three parasites at the concentration tested.
Proteasome-enriched cell lysates were prepared from resistant
cell line RES II, which maintains mutations encoding a G197C
substitution in the β5 subunit as well as a T30A substitution in the
β4 subunit. The chymotrypsin-like activity within this lysate was
insensitive to inhibition by 8 up to concentrations of 100 μM (IC50 >
100 μM for RES II compared with IC50 = 0.16 ± 0.01 μM for WT
L. donovani proteasomes). Lysates prepared from RES II were
similarly insensitive to all of the compounds within the compound 8
series. Collectively, these data confirm that the proteasome is the
primary target of 8. Interestingly, bortezomib and carfilzomib, two
anticancer drugs known to inhibit the chymotrypsin-like activity of
human and T. cruzi proteasomes (20), inhibited this activity in ly-
sates prepared from RES II and WT parasites with equal potency.
These findings are consistent with the failure of RES I and RES III
to demonstrate cross-resistance to bortezomib (SI Appendix, Fig.
S7A) and suggest that 8 and its analogs may bind to a site that is
distinct from bortezomib and carfilzomib binding sites. In contrast,
RES I and RES II did demonstrate significant levels of cross-re-
sistance to GNF6702, suggesting that these compounds do share a
similar binding site (SI Appendix, Fig. S7B).
Morphological Changes and Cell Cycle Defects. Profound morpho-
logical changes were evident in parasites treated with compounds
from this series. To gain additional insight into these compound-
induced changes, L. donovani promastigotes were treated with 7
at a concentration equivalent to two times the established EC50
value for 6 h before analysis by transmission EM. Incubation with
7 caused swelling of promastigotes compared with untreated
controls. In addition, there was a significant accumulation of
intracellular vesicles within treated parasites (SI Appendix, Fig.
S8). Based on our target identification studies, we reasoned that
an inability to recycle key proteins via the proteasome left these
parasites overcome by their own waste protein products. This
accumulation of vesicles and associated morphological changes
Fig. 3. Target identification and validation studies in T. brucei and L.
donovani. (A) Genome-wide map indicating RITseq hits from screening of 7.
Multiple RITseq fragments represent primary hits and are indicated in green.
Other loci with mapped reads are indicated in gray. RPKM, reads per kilo-
base of transcript per million mapped reads. (B) Dose–response curves for
WT (white circles) and RES II-resistant cells (black circles) treated with 7. EC50
values of 3.5 ± 0.09 and >1,000 nM were determined for WT and RES II cells,
respectively. (C) EC50 values for WT (white circles) and RES II-resistant cells
(black circles) treated with 8were 14.6 ± 0.3 and >1,000 nM, respectively. (D)
EC50 values for WT (white), β5MUT (black), and β4MUT cells (gray) treated
with 7 were 9.4 ± 0.14, 37.6 ± 0.6, and 11.2 ± 0.2 nM, respectively. All dose–
response curves are the nonlinear regression fits using a two-parameter EC50
equation. Data are the mean ± SD of at least two independent experiments.
Fig. 4. Target validation studies in L. donovani. (A) Dose–response curves
determining the effect of 8 on chymotrypsin-like proteasome activity in ly-
sates of L. donovani (green), purified human 26S proteasomes (red), extracts
of THP-1 monocytes (yellow), and the absence of proteasome (black). (B) A
correlation plot of cellular potency (L. donovani axenic amastigotes; x axis)
and biochemical inhibition of Leishmania proteasome chymotrypsin-like
activity (y axis) for a set of compound 8 analogs. Compound 8 is shown in
red. (C) The proteasome active site probe UbiQ-018 fluorescently and co-
valently labels the β subunits of the proteasome in extracts of L. donovani
WT (i), L. donovani-resistant RES II cells (ii), and human THP-1 monocytes (iii).
At 100 μM, compound 8 selectively blocks labeling of β5 in L. donovani (WT)
but not in THP-1 extracts or extracts from compound 7-resistant L. donovani.
The presence of the panproteasome inhibitor bortezomib (Bz) prevents la-
beling of proteasome subunits in all extracts. Subunit identity was assigned
by mass spectrometry of the bands excised from the gel (details are in SI
Appendix, SI Text and Table S8).
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may also be explained by the activation of autophagy, an estab-
lished consequence of proteasome inhibition (22).
Previous studies have demonstrated that specific inhibition of
the proteasome can lead to cell cycle arrest, with treated cells
accumulating at the G2/M checkpoint due to an inability to de-
grade G2/M-phase control cyclins (23, 24). This prompted us to
analyze the effects of 7 on cell cycle progression in L. donovani and
T. brucei (SI Appendix, Fig. S9). In both cases, treatment with 7
resulted in an accumulation of cells in G2/M and a decrease in the
proportion of cells in G1 and S phases. These findings are entirely
consistent with the compounds from this series inhibiting the
proteasome of kinetoplastid parasites.
Cryo-EM Structure of Compound 8 Bound to the Leishmania tarentolae
20S Proteasome. The potency of 8 against the nonpathogenic
Leishmania spp. Leishmania tarentolae (EC50 value of 40 nM) was
comparable with that achieved against L. donovani promastigotes
(EC50 value of 14 nM). In addition, inhibition of the chymotrypsin-
like activities catalyzed by L. donovani and L. tarentolae protea-
somes by a set of compound 8 analogs correlated extremely well (SI
Appendix, Fig. S10). These data suggest that inhibitor pharmacology
against L. tarentolae is broadly similar to that seen for L. donovani,
providing confidence in the use of this nonpathogenic surrogate for
subsequent structural studies (SI Appendix, Table S9). Apo (3.3 Å)
and 8-liganded (2.8 Å) (Fig. 5A) L. tarentolae 20S proteasome
structures were obtained using single-particle cryo-EM (SI Appen-
dix, Figs. S11–S15 and Table S9).
The binding site and binding mode of 8 could be clearly de-
termined by the excellent quality of the map (Fig. 5 B and C and
SI Appendix, Fig. S16). Unexpectedly, the inhibitor does not bind
in the proposed binding site of GNF6702 (20). The ligand binds
mainly within the β5 subunits proximal to the catalytic T100
residue (Fig. 5D). Hydrogen bonds to the side chain of Y212 (β5)
and to the backbone amides of G228 (β5) and S229 (β5) within
the β5 subdomain all anchor the molecule (Fig. 5D) into a largely
open site that shows great surface complementarity between the
ligand and protein (Fig. 5E). The fluorine atom establishes an
orthogonal multipolar interaction with the backbone carbonyl
carbon of S195 and a weak hydrogen bond with the side chain of
the same residue. The pyrrolidine carboxamide sits in the only
enclosed part of the site in a narrow hydrophobic pocket that is
limited in depth by I29 (β4) and capped by the pi-stacked resi-
dues of F24 (β4) and Y25 (β4) (Fig. 5F). These three amino acids
are completely conserved among L. donovani, T. cruzi, and
T. brucei but become M28 (β4), S23 (β4), and N24 (β4) within the
human protein (Fig. 5F and SI Appendix, Fig. S18). Interestingly,
mutation of these same residues confers resistance to GNF6702
in T. cruzi (20), suggesting that the two series may have over-
lapping binding sites. In comparing the binding mode of 8 with
the binding mode of bortezomib in the human structure (25), it is
possible to observe that the two molecules partially overlap (SI
Appendix, Fig. S19).
Molecular Modeling. To investigate the selectivity of 8 against the
human 20S proteasome and rationalize the role of the single-point
mutations causing resistance, a homology model of the L. donovani
20S proteasome β4 and β5 subunits was generated using the
L. tarentolae 20S proteasome cryo-EM structure as a template. The
L. tarentolae 20S proteasome β4 and β5 subunits are highly ho-
mologous to the L. donovani β4 and β5 subunits (overall sequence
identities of 95 and 98%, respectively), and in particular, the 26
amino acids forming the binding site that recognizes 8 are entirely
conserved, giving the opportunity to build a very robust model (SI
Appendix, Figs. S20 and S21A)
Molecular Basis for Selectivity Against the Human 20S Proteasome.
Despite several differences in the primary sequence, this binding
site can be found in L. donovani, L. tarentolae, and human 20S
proteasomes (SI Appendix, Fig. S21B). However, of the nine
amino acids that are different in the human structure compared
with L. donovani, the majority are located where the pyrrolidine
ring binds. In L. tarentolae, the pyrrolidine ring binds in a hy-
drophobic pocket formed by A23, F24, Y25, I27, and I29 side
chains and K28 backbone from the β4 subunit and Y212, V227,
and Y235 side chains and S231 backbone from the β5 subunit. In
the human proteasome, most of the β4 residues defining this
pocket are different (SI Appendix, Fig. S20), leading to a con-
siderable change in morphology. In the human structure, the
pyrrolidine binding cavity is more open, shallower, and solvent
exposed, thus losing its hydrophobic character (SI Appendix, Fig.
S22). Thus, the human structure is not capable of establishing
the important hydrophobic and π-stacking interactions with the
inhibitor (F24 in L. tarentolae corresponds to S23 in human).
These changes also impact the water molecule network in the
binding site. A set of three highly unstable water molecules can
be identified in the hydrophobic cavity in L. tarentolae, which can
be easily replaced by the ligand on binding. In contrast, due to
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Fig. 5. Experimental cryo-EM structure of 8 bound
to the L. tarentolae 20S proteasome. (A) Two mole-
cules of 8 (space fill) are found in 20S structure
(protein ribbon) bound at the β4/β5 interface. Protein
subunits β4 and β5 of this bound structure are shown
in green and blue, and 8 is shown in magenta. (B and
C) Electron map of the 2.8-Å cryo-EM structure of
L. tarentolae 20S centered on 8 contoured at 3σ (black
mesh); modeled ligand and protein shown as green
lines. (D) A close-up view of the ligand binding site is
shown; β4 residues are in green, are β5 residue labels
are in blue. Polar interactions are indicated with red
dashed lines. (E) Protein surface representation to
highlight the complementarity of the pocket filled
by 8. (F) Structural basis of human selectivity. Key
residue differences are labeled in black. (G) Overlay
with apo structure is shown in gray. The positions of
the two key residues (T30 and G197) where muta-
tions have been observed in L. donovani are shown.
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the polar nature of the side chains (S23, N24) and the exposure
to the bulk of the solvent, the water network in the human
structure is more stable and less easily displaced by the ligand (SI
Appendix, Fig. S23).
Differences in ligand–protein electrostatic complementarity
between the L. tarentolae and human proteasomes can also
provide additional insights into the observed selectivity. A
combination of inductive and mesomeric effects in 8 results in
a nonhomogeneous charge distribution (SI Appendix, Fig. S24 A
and B). In the L. tarentolae structure, the hydrogens on carbon 3
and 4 of the fluorophenyl system are characterized by an accu-
mulation of positive charge that sits in a negatively charged area
of the proteasome defined by D214 and D215 (SI Appendix, Fig.
S24 C and D). In the human structure, one of the negatively
charged residues is lost as D215 replaces S215, decreasing the
negative character of the binding site and impacting the strength
of the dipole–charge interaction with the ligand. Other residues
within the β5 subunit are generally conserved or do not impact
ligand binding. In the morpholine binding region of L. tarentolae,
A268 changes to tyrosine but does not clash with the ligand.
Drug Resistance Mutations. The structural basis of the resistance
mutations identified in our studies [G197S (β5), G197C (β5), and
T30A (β4)] can be rationalized based on the distinct inhibitor site
that we have uncovered. The alpha carbon of G197 forms part of
the floor of the ligand binding pocket just below the fluorophenyl
ring (Fig. 5G). The presence of the larger hydrophilic side chain in
the serine and cysteine mutants would result in a steric clash with
this fused aromatic system and would be detrimental to inhibitor
activity. In contrast, T30A (β4) has no direct interactions with the
ligand. It lies at a pivot point between the β4 and β5 subunits,
allowing the β loop, which contains I29 (β4), F24 (β4), and Y25
(β4), to wedge open to create the pyrrolidine pocket. Comparison of
the apo and liganded structures obtained by cryo-EM suggests that
a T30A mutation would alter the ease of this motion, changing the
access to this slim pocket, which is important for activity and se-
lectivity (Fig. 5G). In addition, T30 establishes a hydrogen bond
with Q222 (β5). These interactions seem to provide an anchor point
to the β-sheet in β5 (L224–V227) that defines the binding site for
8. A T30A mutation would remove the anchor point, introducing
instability to the binding site.
Conclusion
Here, we describe the development of a preclinical candidate for
VL. This compound acts through inhibition of the chymotrypsin-
like activity catalyzed by the β5 subunit of the L. donovani pro-
teasome, demonstrating good selectivity over the human enzyme.
The compound selectively inhibits the parasite enzyme. High-
resolution cryo-EM structures of apo and 8-bound L. tarentolae
20S proteasome have revealed a previously undiscovered binding
site for inhibitors of the chymotrypsin-like activity. This site lies
between the β4 and β5 subunits and exploits an induced cavity
that is lined on one side by β4 residues that are divergent be-
tween human and kinetoplastid protozoan. While this binding
pocket differs from the cavity suggested by Khare et al. (20) in T.
cruzi, which accommodates GNF6702, it is consistent with all of
our experimental observations and mutational data. Compound
8 is currently undergoing preclinical development, and it is ad-
vancing toward human clinical trials. The data generated to date
provide every reason to believe that 8 can become a much-
needed safe oral treatment for patients suffering from this dev-
astating neglected tropical disease.
Materials and Methods
All regulated procedures, at the University of Dundee, on living animals was
carried out under the Animals (Scientific Procedures) Act 1986, as amended in
2012 (and in compliance with European Union Directive EU/2010/63). All
animal studies were reviewed by GlaxoSmithKline’s (GSK) internal ethical
review committee and performed in accordance with Animals (Scientific
Procedures) Act 1986 and the GSK Policy on the Care, Welfare, and Treat-
ment of Laboratory Animals (UK 1986). Usage of human-sourced macro-
phages was approved by the Scottish National Blood Transfusion Service
committee for the governance of blood and tissue samples for non-
therapeutic use, and donor research, and was in accord with the terms of the
informed consents. Full details are in SI Appendix. This includes the follow-
ing information: (i) the chemical synthesis of compounds described in the
paper, (ii) the methods for in vitro parasite assays, (iii) the methods for
in vitro and in vivo drug metabolism and pharmacokinetics, (iv) the methods
for efficacy studies, (v) the methods for preclinical safety studies, (vi) the
methods for mode of action studies, (vii) details of cryo-EM studies, (viii)
details of molecular modeling studies, and (ix) ethical statements.
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